Front > Comment > Gali Weinreb

Gali Weinreb

Migraine market starts to look tough for Teva

The enthusiasm over FDA approval for Teva's migraine treatment has waned.

Israeli biotechs - the horrible truth

American industry commentator Adam Feuerstein shouted what many whisper - but the horror isn't just one way.

Teva's future as an Israeli company in jeopardy

Only 10% of Teva's shares are owned by Israelis and after the cuts only 8% of employees will be Israeli.

NeuroDerm fulfills a medical and commercial dream

Continuous treatment of Parkinson's disease will enable patients to tolerate the drugs better for longer.

Gali Weinreb  illustration: Gil Gibli Compugen was worth the wait

Compugen shows life sciences companies that invest heavily in science can achieve a breakthrough, even after the capital market has given up on them.

Gali Weinreb  illustration: Gil Gibli Ben-Haim's lawsuits almost equal his exits

Biotech billionaire Prof. Shlomo Ben-Haim is facing his third lawsuit this year and fourth in his career over the life sciences companies he founded.

Gali Weinreb  illustration: Gil Gibli Given Imaging pill won't replace colonoscopy

Given Imaging told the US Food and Drug Administration (FDA) today that it will not be seeking the replacement of colonoscopies with its pill.

Gali Weinreb  illustration: Gil Gibli Levin sets scene for Teva cuts

New Teva CEO Dr. Jeremy Levin has already said that part of his strategy will be greater "budgetary discipline."

Gali Weinreb  illustration: Gil Gibli Teva's problems are delayed, not solved

The eventual expiration of Copaxone's patents will still cause a huge hole in Teva's revenue and profits.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018